TSCAN THERAPEUTICS INC (TCRX)
US89854M1018 - Common Stock
We assign a fundamental rating of 3 out of 10 to TCRX. TCRX was compared to 588 industry peers in the Biotechnology industry. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, TCRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TCRX had negative earnings in the past year.
In the past year TCRX has reported a negative cash flow from operations.
TCRX had negative earnings in each of the past 5 years.
In the past 5 years TCRX always reported negative operating cash flow.
1.2 Ratios
TCRX has a Return On Assets of -32.78%. This is in the better half of the industry: TCRX outperforms 69.35% of its industry peers.
TCRX has a better Return On Equity (-59.14%) than 62.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.78% | ||
| ROE | -59.14% | ||
| ROIC | N/A |
ROA(3y)-30.63%
ROA(5y)-34.42%
ROE(3y)-52%
ROE(5y)-68.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCRX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TCRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.14, we must say that TCRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.14, TCRX is in the better half of the industry, outperforming 62.33% of the companies in the same industry.
TCRX has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.18, TCRX is not doing good in the industry: 67.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.14 |
ROIC/WACCN/A
WACC9.19%
2.3 Liquidity
TCRX has a Current Ratio of 6.51. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TCRX (6.51) is better than 65.92% of its industry peers.
A Quick Ratio of 6.51 indicates that TCRX has no problem at all paying its short term obligations.
TCRX has a Quick ratio of 6.51. This is in the better half of the industry: TCRX outperforms 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.51 | ||
| Quick Ratio | 6.51 |
3. Growth
3.1 Past
TCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.27%, which is quite impressive.
The Revenue has grown by 55.47% in the past year. This is a very strong growth!
TCRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 168.29% yearly.
EPS 1Y (TTM)31.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q73.08%
Revenue 1Y (TTM)55.47%
Revenue growth 3Y168.29%
Revenue growth 5YN/A
Revenue growth Q2Q132.61%
3.2 Future
TCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
Based on estimates for the next years, TCRX will show a very strong growth in Revenue. The Revenue will grow by 25.99% on average per year.
EPS Next Y43.2%
EPS Next 2Y18.36%
EPS Next 3Y11.5%
EPS Next 5Y6.39%
Revenue Next Year-1.99%
Revenue Next 2Y-17.85%
Revenue Next 3Y-17.39%
Revenue Next 5Y25.99%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.36%
EPS Next 3Y11.5%
5. Dividend
5.1 Amount
No dividends for TCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSCAN THERAPEUTICS INC
NASDAQ:TCRX (4/25/2024, 4:20:00 PM)
After market: 7.43 +0.14 (+1.92%)7.29
-0.09 (-1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap349.19M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.78% | ||
| ROE | -59.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.51 | ||
| Quick Ratio | 6.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y43.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)55.47%
Revenue growth 3Y168.29%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y